DEM
CRDL

Disciplined Equity Management’s Cardiol Therapeutics CRDL Stock Holding History

Disciplined Equity Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-500
Closed -$605 – 46
2025
Q4 		$605 Buy
+500
New +$524 ﹤0.01% 60

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Disciplined Equity Management's CRDL Position: Q1 2026 in Review

Disciplined Equity Management sold out of Cardiol Therapeutics (CRDL) in Q1 2026, closing a stake of 500 shares — an estimated $605 sold.

Disciplined Equity Management first reported a position in CRDL in Q4 2025 and held it in 1 quarter. The position peaked at $605 in Q4 2025. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Disciplined Equity Management reported no remaining Cardiol Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Disciplined Equity Management sold 500 Cardiol Therapeutics shares in Q1 2026, an estimated $605.
  • Disciplined Equity Management first reported a position in Cardiol Therapeutics in Q4 2025 and held it in 1 quarter.
  • Disciplined Equity Management's Cardiol Therapeutics position peaked at $605 in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Disciplined Equity Management's 13F filing for Q1 2026, filed 28 Apr 2026.